Results 121 to 130 of about 10,965 (175)

Advances in molecular glue degraders for targeted protein degradation: Focus on NEK7, WEE1, CDK2, GSPT1 and VAV1. [PDF]

Asian J Pharm Sci
Cheng B, Wang Y, Hong Y, Zhou Y, Peng X, Chen J, Zeng C.   +6 more
europepmc   +1 more source

Pharmacological WEE1 inhibition as a strategy to overcome cisplatin resistance in non-seminoma testicular cancer: insights from preclinical models. [PDF]

Sci Rep
Tamburello M, Boldini C, Abate A, Salvi V, Valcamonico F, Laganà M, Cosentini D, Suardi NR, Mirabella G, Altieri B, Sigala S.   +10 more
europepmc   +1 more source

Patient-specific modeling of G2/M cell cycle dynamics reveals prognostic dynamical regimes driven by copy number alterations. [PDF]

NPJ Syst Biol Appl
Tonina A, Romanel A.
europepmc   +1 more source

Combination AURKA and WEE1 Inhibition Exhibits Efficacy in EGFR or Pan-ERBB Inhibitor-Resistant Head and Neck Squamous Cell Carcinoma. [PDF]

Cancer Res Commun
Silva FN, Lee JW, Nguyen TT, Goeckel FM, Bagnyukova T, Borghaei H, Golemis EA, Burtness BA.   +7 more
europepmc   +1 more source

Drug Repositioning in Kinase Inhibitor Discovery for Cancer Therapy. [PDF]

Pharmaceutics
Sun Q, Pang X, Liu W.
europepmc   +1 more source

Current Research in Polypharmacology for Cancer Treatment Using Dual-Target Histone Deacetylase Inhibitors. [PDF]

Int J Mol Sci
Yudaev P, Aleksandrova Y, Neganova M.
europepmc   +1 more source

Greatwall depletion from Xenopus oocytes reveals a key role of the cyclin B/CDK1-PP2A-B55 balance in the coordination of meiotic events. [PDF]

Nat Commun
Roque S, Ben Choug C, Khodja CH, Vigneron S, Legros V, Chevreux G, Lacroix B, Castro A, Lorca T.   +8 more
europepmc   +1 more source

WEE1 Inhibitor: Clinical Development [PDF]

Current Oncology Reports, 2021
Abstract Purpose of Review WEE1 inhibitor has been shown to potential chemotherapy or radiotherapy sensitivity in preclinical models, particularly in p53-mutated or deficient cancer cells although not exclusively. Here, we review the clinical development of WEE1 inhibitor in combination with chemotherapy or radiotherapy ...
Anthony Kong, Hisham Mehanna
exaly   +4 more sources

Some of the next articles are maybe not open access.

Related searches:

SIRT1 deacetylates WEE1 and sensitizes cancer cells to WEE1 inhibition

Nature Chemical Biology, 2023
The cell-cycle checkpoint kinase WEE1 is emerging as a therapeutic target for cancer treatment. However, how its catalytic activity is regulated remains poorly understood, and reliable biomarkers for predicting response to WEE1 inhibitor remain to be identified.
Xiaomei Zhu, Qunshu Su, Haiyuan Xie, Lizhi Song, Fan Yang, Dandan Zhang, Binghong Wang, Shixian Lin, Jun Huang, Mengjie Wu, Ting Liu   +10 more
openaire   +2 more sources

Targeting WEE1 Kinase in Cancer

Trends in Pharmacological Sciences, 2016
WEE1 kinase plays a crucial role in the G2-M cell-cycle checkpoint arrest for DNA repair before mitotic entry. Normal cells repair damaged DNA during G1 arrest; however, cancer cells often have a deficient G1-S checkpoint and depend on a functional G2-M checkpoint for DNA repair. WEE1 is expressed at high levels in various cancer types including breast
Donald S. Backos, Philip Reigan, Christopher Matheson   +2 more
exaly   +3 more sources